title: Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
abstract: BACKGROUND
  Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is associated with an aggressive form of the disease with significantly shortened disease free and overall survival. In recent years, the use of HER2-targeted therapies, monoclonal-antibodies and small molecule tyrosine-kinase inhibitors has significantly improved the clinical outcome for HER2-positive breast-cancer patients. However, only a fraction of HER2-amplified patients will respond to therapy and the use of these treatments is often limited by tumour drug insensitivity or resistance and drug toxicities. Currently there is no way to identify likely responders or rational combinations with the potential to improve HER2-focussed treatment outcome.
  
  
  METHODS
  In order to further understand the molecular mechanisms of treatment-response with HER2-inhibitors, we used a highly-optimised and reproducible quantitative label-free LC-MS strategy to characterize the proteomes of HER2-overexpressing breast-cancer cell-lines (SKBR3, BT474 and HCC1954) in response to drug-treatment with HER2-inhibitors (lapatinib, neratinib or afatinib).
  
  
  RESULTS
  Following 12 ours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 μM), 21 proteins changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following afatinib treatment (150 nM). Whereas following 24 hours treatment with neratinib (200 nM) 46 proteins changed significantly in abundance in the HCC1954 cell-line and 23 proteins in the SKBR3 cell-line compared to the untreated cells. Analysing the data we found that, proteins like trifunctional-enzyme subunit-alpha, mitochondrial; heterogeneous nuclear ribonucleoprotein-R and lamina-associated polypeptide 2, isoform alpha were up-regulated whereas heat shock cognate 71 kDa protein was down-regulated in 3 or more comparisons.
  
  
  CONCLUSIONS
  This proteomic study highlights several proteins that are closely associated with early HER2-inhibitor response and will provide a valuable resource for further investigation of ways to improve efficacy of breast-cancer treatment.
authors.affiliation: National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland. alessiodiluca@gmail.com.
authors.forename: Alessio
authors.initials: A
authors.lastname: Di Luca
authors.affiliation: National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland. michael.henry@dcu.ie.
authors.forename: Michael
authors.initials: M
authors.lastname: Henry
authors.affiliation: National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland. paula.meleady@dcu.ie.
authors.forename: Paula
authors.initials: P
authors.lastname: Meleady
authors.affiliation: National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland. robert.oconnor@dcu.ie.|School of Nursing and Human Sciences, DCU, Glasnevin, Dublin 9, Dublin, Ireland. robert.oconnor@dcu.ie.
authors.forename: Robert
authors.initials: R
authors.lastname: O'Connor
mesh_terms: D000077716:Afatinib; D001943:Breast Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D005260:Female; D006801:Humans; D000077341:Lapatinib; D013058:Mass Spectrometry; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D040901:Proteomics; D011799:Quinazolines / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000077716:Afatinib; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011804:Quinolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C487932:neratinib